Navigation Links
Keryx Biopharmaceuticals to Present at the 25th Annual ROTH Conference
Date:3/14/2013

NEW YORK, March 14, 2013 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur , the Company's Chief Executive Officer, will be presenting at the upcoming 25th Annual ROTH Conference, to be held March 17th -20th in Dana Point, California.  Mr. Bentsur's presentation is scheduled to take place on Monday, March 18th, at 10:00 AM PT (1:00 PM ET). 

A live audio webcast of Mr. Bentsur's presentation will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of the webcast will be available following the conclusion of the live presentation.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. Keryx is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Keryx has completed a U.S.-based Phase 3 clinical program for Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA, and Keryx expects to submit a New Drug Application with the FDA in the second quarter of 2013 and a Marketing Authorization Application with the EMA in mid-2013.  Zerenex is also in Phase 2 development in the U.S. for the management of phosphorus and iron deficiency in anemic patients with Stages 3 to 5 non-dialysis dependent chronic kidney disease.  In addition, Keryx's Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. has filed its New Drug Application for marketing approval of ferric citrate in Japan for the treatment of hyperphosphatemia in patients with chronic kidney disease.  Keryx is headquartered in New York City.

KERYX CONTACT:
Lauren Fischer
Director - Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965
E-mail: lfischer@keryx.com


'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
3. Keryx Biopharmaceuticals Announces Live Webcast of Upcoming Analyst Day
4. Keryx Biopharmaceuticals to Present at The 7th Annual JMP Securities Healthcare Conference
5. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess of $100,000 Investing In Keryx Biopharmaceuticals, Inc. To Contact the Firm
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
7. Keryx Biopharmaceuticals to Present at the 15th Annual BIO CEO & Investor Conference Presentation Scheduled for Monday, February 11th at 2:30 PM ET
8. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
9. Inspiration Biopharmaceuticals Announces Filing of Biologics License Application (BLA) for IB1001, a Recombinant Factor IX Product for People with Hemophilia B
10. Global Biopharmaceuticals Market 2011-2015
11. Inspiration Biopharmaceuticals Expands Industry Expertise with Five New Executive Hires
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... The immunohistochemistry (IHC) market is projected ... of 7.3% during the forecast period of 2016 to 2021 dominated ... accounted for the largest share of immunohistochemistry (IHC) market, by end ... , , ... market spread across 225 pages, profiling 10 companies and supported with ...
(Date:11/30/2016)... 30, 2016 The global Pyrogen ... hold a dominant share in the overall market. The ... Inc., and Merck KGaA, held a lion,s share of ... Research observes that these companies are expected to retain ... that are do not require rabbit pyrogen testing along ...
(Date:11/30/2016)... 30, 2016 /PRNewswire/ -  Equicare Health Inc ., the ... recognized as one of the top 100 companies in ... listing that distinguishes the top digital health companies across ... step forward this year continually upgrading our product with ... base and team," says Len Grenier , CEO ...
(Date:11/30/2016)... 2016 Part of 5m$ Investment in ... ... Aptuit, LLC today announced that it had successfully completed the ... compounds have increased the Screening Collection to over 400,000. The ... capabilities of the company. This expansion, complemented by new robotics ...
Breaking Biology Technology:
(Date:11/22/2016)... 2016   MedNet Solutions , an innovative SaaS-based ... clinical research, is pleased to announce that the company ... Life Sciences Awards as "Most Outstanding in eClinical ... year of recognition and growth for MedNet, which has ... iMedNet ™ , MedNet,s flagship ...
(Date:11/17/2016)... Calif. , Nov. 17, 2016  AIC announces that it has just released ... in organizations that require high-performance scale-out plus high speed data transfer storage solutions. ... ... ... Setting up a high ...
(Date:11/14/2016)... Technology, Inc. ("xG" or the "Company") (Nasdaq: XGTI, XGTIW), ... in challenging operating environments, announced its results for the ... a conference call to discuss these results on November ... Key Recent Accomplishments ... acquire Vislink Communication Systems. The purchase is expected to ...
Breaking Biology News(10 mins):